Recombinant human interleukin-11 (Qilu Pharmaceutical)

重组人白介素-11（齐鲁制药）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-11 (Qilu Pharmaceutical)
Drug Alias Name重组人白介素11（齐鲁制药）注射用重组人白介素-11（齐鲁制药）巨和粒
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionThrombopoiesis stimulantsInterleukin 11 receptor alpha stimulants
TargetsInterleukin 11 receptor alpha
Therapy Area/IndicationsThrombocytopenia
Global Approved IndicationsThrombocytopenia
Approved Indications in ChinaThrombocytopenia
Original Approved Country/TerritoryMainland China
Original Approved Date2003/03/18
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsThrombocytopenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AC02
Related LinksN/A